In the Original Investigation titled “Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis,” published online June 12, 2023, there were errors in the point estimate and error bars in Figure 2A and in the graph labels in Figure 4. The point estimate and error bars were adjusted for accuracy, and the graph labels were switched, respectively. This article was corrected online.